PR Newswire - Fosun Pharma Announces 2024Q3 Financial Results...
Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 30, 2024 /PRNewswir...
Read More

ภาษาไทย
English